FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person [*] Silva Francisco			2. Issuer Name and Ticker or Trading Symbol BioRestorative Therapies, Inc. [BRTX]		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
				X	Director	10% Owner				
(Last) (First) (Middle) 40 MARCUS DRIVE		(Middlo)	—	X	Officer (give title below)	Other (specify below)				
		(Midule)	3. Date of Earliest Transaction (Month/Day/Year) 03/18/2022		VP of Research and	, ,				
(Street) MELVILLE	NY	11747	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv X	idual or Joint/Group Filing Form filed by One Repo	· · · · /				
(City)	(State)	(Zip)	Devivative Convertion Associated Disposed of an Dave							

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	(Instr. 3 and 4)		(Instr. 4)
Common Stock	03/18/2022		Α		12,438	Α	(1)	161,286 ⁽²⁾	D	
Common Stock								11,829	Ι	IRA

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (Ir 8)	tion str.	Derivative Ex		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	<u> </u>	
Stock Option	\$3,000							(3)	05/02/2022	Common Stock	1		1	D	
Stock Option	\$3,000							(3)	12/07/2022	Common Stock	1		1	D	
Stock Option	\$3,000							(3)	10/04/2023	Common Stock	1		1	D	
Stock Option	\$3,000							(3)	02/18/2024	Common Stock	3		3	D	
Stock Option	\$3,000							03/12/2014	03/11/2024	Common Stock	1		1	D	
Stock Option	\$3,000							04/14/2014	05/02/2022	Common Stock	1		1	D	
Stock Option	\$3,000							(3)	10/23/2024	Common Stock	9		9	D	
Stock Option	\$3,000							(3)	09/04/2025	Common Stock	6		6	D	
Stock Option	\$3,000							(3)	06/10/2026	Common Stock	15		15	D	
Stock Option	\$3,000							(3)	07/12/2027	Common Stock	20		20	D	
Stock Option	\$3,000							(3)	10/29/2028	Common Stock	25		25	D	
Stock Option	\$13.5							(4)	03/18/2031	Common Stock	293,479		293,479	D	
Stock Option	\$13.5							(5)	11/04/2031	Common Stock	42,059		42,059	D	

Explanation of Responses:

1. Shares received pursuant to a restricted stock unit grant. Vests in twelve nearly equal monthly installments beginning on April 18, 2022.

2. Includes 110,264 shares received pursuant to unvested restricted stock unit grants. Such shares vest to the extent of 1,037 shares beginning on April 18, 2022 and continuing monthly through September 18, 2022, 1,036 shares beginning on October 18, 2022 and continuing monthly through February 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024.

3. The option is currently exercisable.

4. The option vests and becomes exercisable to the extent of 146,740 shares on March 18, 2021, 36,684 shares on November 4, 2021 and the remaining 110,055 shares in six nearly equal quarterly installments beginning December 18, 2021 and continuing every three months thereafter until fully vested.

5. The option vests and becomes exercisable to the extent of 21,030 shares on November 4, 2021 with the remaining 21,029 shares vesting quarterly in eight nearly equal installments beginning on November 4, 2022.

/s/ Francisco Silva

03/22/2022 ** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.